Savara Inc (NAS:SVRA)

$ 3.305 -0.055 (-1.64%) Market Cap: 567.20 Mil Enterprise Value: 383.91 Mil PE Ratio: 0 PB Ratio: 2.82 GF Score: 38/100

Savara Inc at Guggenheim Healthcare Talks Biotechnology Conference Transcript
Feb 07, 2024
Savara Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Savara Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Savara Inc Annual Shareholders Meeting Transcript
Jun 10, 2021
Q2 2020 Savara Inc Earnings Call Transcript
Aug 06, 2020

$2.04 (-3.77%)

Earnings
Savara Inc Annual Shareholders Meeting Transcript
May 27, 2020
Q1 2020 Savara Inc Earnings Call Transcript
May 07, 2020

$2.55 (+5.81%)

Earnings
Savara Inc. - Special Call Transcript
Apr 03, 2020
Q4 2019 Savara Inc Earnings Call Transcript
Mar 12, 2020

$2.55 (+8.05%)

Earnings
Q3 2019 Savara Inc Earnings Call Transcript
Nov 07, 2019

$0.91 (-1.09%)

Earnings
Q2 2019 Savara Inc Earnings Call Transcript
Aug 08, 2019

$2.51 (+2.03%)

Earnings
Savara Inc Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) Transcript
Jun 12, 2019
Q1 2019 Savara Inc Earnings Call Transcript
May 09, 2019

$10.72 (-2.46%)

Earnings
Q4 2018 Savara Inc Earnings Call Transcript
Mar 13, 2019

$8.6 (+1.30%)

Earnings

Savara Inc. - Special Call Transcript

Apr 03, 2020 / 12:30PM GMT

Release Date Price: $1.8 (-3.23%)

Transcript

Operator

Welcome to the Savara conference call. (Operator Instructions) An audio webcast of this call will be available on the Investors section of Savara's website at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction or transmission of this call without the expressed written consent of Savara is strictly prohibited. As a reminder, today's call is being recorded.

I would now like to turn the phone over to Anne Erickson, Head of Investor Relations and Corporate Communications at Savara.

Anne Erickson

Savara Inc. - VP of IR & Corporate Communications

Good morning, everyone, and thank you for joining us today. We hope you had an opportunity to review the press release that we issued yesterday afternoon, April 2, 2020, announcing our licensing agreement for the Phase III investigational drug candidate Apulmiq. The release can be found on the Investors section of our website at savarapharma.com. If you've not received it or you'd like to be added to the company's distribution list, please e-mail me

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.